Biotinylated Human TL1A / TNFSF15 Protein, His, Avitag
分子別名（Synonym）
TL1A, VEGI, TNFSF15
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human TL1A Protein, His,Avitag (TLA-H52Q1) is expressed from human 293 cells (HEK293). It contains AA Leu 72- Leu 251 (Accession # O95150-1).
Predicted N-terminus: His
蛋白結構（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 24.1 kDa. The protein migrates as 28-32 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
標記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
內毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
TNF樣細胞因子1A（TL1A）及其受體、死亡受體3（DR3）和誘餌受體3（DcR3）分別是TNF和TNF受體蛋白超家族的成員。APC衍生的TL1A與淋巴細胞DR3的結合為活化的淋巴細胞提供了共刺激信號。DR3信號不僅影響效應淋巴細胞的增殖活性和細胞因子的產生，還嚴重影響調節(jié)性T細胞的發(fā)育和抑制功能。然而，DcR3限制了TL1A/DR3復合物的功能：減弱T細胞活化并下調促炎細胞因子的分泌。與DR3和DcR3一起，TL1A構成了一個細胞因子系統(tǒng)，積極干擾免疫反應的調節(jié)。
關鍵字： TL1A;TL1A蛋白;TL1A重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。